tbuckley/cabot-search huggingface dataset:
Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs
Authors: Camille P Figueiredo, Holger Bang, Jayme Fogagnolo Cobra, Matthias Englbrecht, Axel J Hueber, Judith Haschka, Bernhard Manger, Arnd Kleyer, Michaela Reiser, Stephanie Finzel, Hans-Peter Tony, Stefan Kleinert, Joerg Wendler, Florian Schuch, Monika Ronneberger, Martin Feuchtenberger, Martin Fleck, Karin Manger, Wolfgang Ochs, Matthias Schmitt-Haendle, Hanns-Martin Lorenz, Hubert Nuesslein, Rieke Alten, Joerg Henes, Klaus Krueger, Jürgen Rech, Georg Schett
Journal: Annals of the Rheumatic Diseases (2016)

To perform a detailed analysis of the autoantibody response against post-translationally modified proteins in patients with rheumatoid arthritis (RA) in sustained remission and to explore whether its composition influences the risk for disease relapse when tapering disease modifying antirheumatic drug (DMARD) therapy.Immune responses against 10 citrullinated, homocitrullinated/carbamylated and acetylated peptides, as well as unmodified vimentin (control) and cyclic citrullinated peptide 2 (CCP2) were tested in baseline serum samples from 94 patients of the RETRO study. Patients were classified according to the number of autoantibody reactivities (0-1/10, 2-5/10 and >5/10) or specificity groups (citrullination, carbamylation and acetylation; 0-3) and tested for their risk to develop relapses after DMARD tapering. Demographic and disease-specific parameters were included in multivariate logistic regression analysis for defining the role of autoantibodies in predicting relapse.Patients varied in their antimodified protein antibody response with the extremes from recognition of no (0/10) to all antigens (10/10). Antibodies against citrullinated vimentin (51%), acetylated ornithine (46%) and acetylated lysine (37%) were the most frequently observed subspecificities. Relapse risk significantly (p=0.011) increased from 18% (0-1/10 reactivities) to 34% (2-5/10) and 55% (>5/10). With respect to specificity groups (0-3), relapse risk significantly (p=0.021) increased from 18% (no reactivity) to 28%, 36% and finally to 52% with one, two or three antibody specificity groups, respectively.The data suggest that the pattern of antimodified protein antibody response determines the risk of disease relapse in patients with RA tapering DMARD therapy.2009-015740-42; Results.
Better working environments could boost recruitment to anaesthesia, says study
Authors: Matthew Limb
Journal: BMJ (2016)

More supportive working and learning environments for anaesthesia trainees would help tackle problems of low recruitment and high attrition in the specialty, researchers have said.

Researchers from Aberdeen University looked at the factors influencing the trainees’ decisions about their careers. They also found concerns about the impact of service demands on training quality.

The researchers said that, although many acute hospital specialties were experiencing low recruitment and high attrition of trainees, there had been little research exploring why anaesthesia may or may not be an attractive medical career option in the …
Predicting Malignant Nodules from Screening CT Scans
Authors: Samuel Hawkins, Hua Wang, Ying Liu, Alberto Garcia, Olya Stringfield, Henry Krewer, Qian Li, Dmitry Cherezov, Robert A. Gatenby, Yoganand Balagurunathan, Dmitry Goldgof, Matthew B. Schabath, Lawrence Hall, Robert J. Gillies
Journal: Journal of Thoracic Oncology (2016)
Reconstitution Of EBV-Specific Immunity In Adult Recipients Of Double Cord Blood Transplantation Depends On SCF and IL-7 Levels and Maintenance Of a Diverse TCR Repertoire
Authors: Ioannis Politikos, Haesook Kim, Sarah Nikiforow, Anoma Nellore, Lequn Li, Sean McDonough, Robert J. Soiffer, Joseph H. Antin, Karen K. Ballen, Corey S. Cutler, Jerome Ritz, Vassiliki A. Boussiotis
Journal: Blood (2013)
Malagasy Genetic Ancestry Comes from an Historical Malay Trading Post in Southeast Borneo
Authors: Nicolas Brucato, Pradiptajati Kusuma, Murray P. Cox, Denis Pierron, Gludhug A. Purnomo, Alexander Adelaar, Toomas Kivisild, Thierry Letellier, Herawati Sudoyo, François-Xavier Ricaut
Journal: Molecular Biology and Evolution (2016)

Malagasy genetic diversity results from an exceptional protoglobalization process that took place over a thousand years ago across the Indian Ocean. Previous efforts to locate the Asian origin of Malagasy highlighted Borneo broadly as a potential source, but so far no firm source populations were identified. Here, we have generated genome-wide data from two Southeast Borneo populations, the Banjar and the Ngaju, together with published data from populations across the Indian Ocean region. We find strong support for an origin of the Asian ancestry of Malagasy among the Banjar. This group emerged from the long-standing presence of a Malay Empire trading post in Southeast Borneo, which favored admixture between the Malay and an autochthonous Borneo group, the Ma'anyan. Reconciling genetic, historical, and linguistic data, we show that the Banjar, in Malay-led voyages, were the most probable Asian source among the analyzed groups in the founding of the Malagasy gene pool.
Hybrid anisotropic nanostructures for dual-modal cancer imaging and image-guided chemo-thermo therapies
Authors: Ruiping Zhang, Kai Cheng, Alexander L. Antaris, Xiaowei Ma, Min Yang, Sindhuja Ramakrishnan, Guifeng Liu, Alex Lu, Hongjie Dai, Mei Tian, Zhen Cheng
Journal: Biomaterials (2016)
Endpiece: To die
Authors: Brian Cornelson
Journal: BMJ (2003)

The verb   is one of the few that is only readily usable in the past and future tenses. We accept  died last year, and  can easily accept, we will all die someday. But the present tense, I die, you die, he dies—that should be cancelled right out of the language. And to have to use the verb in that tense not for a single moment but for weeks and months and then years—that is altogether intolerable. We tend to think, furthermore, that   is a verb of the instant, like  dive. It is a thing that takes almost no measurable time. One second you are on the board, looking at the water, and the next second you have left the board behind you and taken the plunge. So with many deaths—one second you are alive, and the next second you are dead. Science defines death in this way, and on your death certificate indicates a particular moment as the moment of death. But sometimes the verb   is more like the verb  age, and is a thing that happens by terrible and slow and imperceptible degrees. My mother was not given a chance to age in that manner, and was, by way of inadequate compensation, given an experience of death as gradual as a life span.

Andrew Solomon

The Stone Boat, 1994
GPs should have direct access to wider range of tests for suspected cancer, says NICE
Authors: Susan Mayor
Journal: BMJ (2016)

GPs should have direct access to a wider range of tests for people with suspected cancer including diagnostic endoscopy, ultrasound, x ray, and scans, the National Institute for Health and Care Excellence (NICE) has recommended in a new quality standard aiming to speed up cancer diagnosis.1

The quality standard sets out measures the NHS should include in planning and delivering services. In addition to recommending that GPs have direct access to ultrasound, x ray, magnetic resonance imaging (MRI), and …
Phase I Study of Dose-Adjusted-Teddi-R with Ibrutinib in Untreated and Relapsed/Refractory Primary CNS Lymphoma
Authors: Kieron Dunleavy, Catherine E. Lai, Mark Roschewski, Jennifer N Brudno, Brigitte Widemann, Stefania Pittaluga, Elaine S Jaffe, Andrea N Lucas, Maryalice Stetler-Stevenson, Constance M. Yuan, Pamela Harris, Diane Cole, John A Butman, Richard F Little, Louis M Staudt, Wyndham H Wilson
Journal: Blood (2015)
PD-035 Efficacy and safety of second-line irinotecan based chemotherapy in early relapse patients with gastric cancer after adjuvant chemotherapy: exploratory subgroup analysis of TRICS trial
Authors: K. Nishikawa, K. Fujitani, H. Inagaki, Y. Akamaru, S. Tokunaga, M. Takagi, S. Tamura, N. Sugimoto, T. Shigematsu, T. Yoshikawa, T. Ishiguro, M. Nakamura, T. Yamane, M. Yamada, M. Imano, S. Iijima, A. Nashimoto, S. Morita, Y. Miyashita, A. Tsuburaya, J. Sakamoto, T. Tsujinaka
Journal: Annals of Oncology (2016)
Molecular Imaging of Fibrin Deposition in Deep Vein Thrombosis Using Fibrin-Targeted Near-Infrared Fluorescence
Authors: Tetsuya Hara, Brijesh Bhayana, Brian Thompson, Chase W. Kessinger, Ashok Khatri, Jason R. McCarthy, Ralph Weissleder, Charles P. Lin, Guillermo J. Tearney, Farouc A. Jaffer
Journal: JACC. Cardiovascular imaging (2012)
The Resource-Based Relative Value Scale
Authors: R W Carter
Journal: JAMA (1989)

<h3>To the Editor. —</h3> The determination by Hsiao et al<sup>1</sup>of the resource-based relative value (RBRV) of a given medical service can be summarized as: RBRV = (<i>TW</i>)(1 +<i>RPC</i>)(1 +<i>AST</i>) where<i>TW</i>is the total work input by the physician,<i>RPC</i>is an index of relative specialty practice costs, and<i>AST</i>is an index of amortized value for the opportunity cost of specialty training. Logically, one would assume that, on the whole, the<i>RPC</i>factors for a given specialty should reflect the cost of providing the work of that specialty, in the same way that<i>TW</i>represents the work provided by that specialty. Instead, Hsiao et al have built their scheme on an<i>RPC</i>factor that represents the cost of generating a given amount of revenue in 1983. A problem arises in that an<i>RPC</i>based on the fraction of 1983 gross revenues will be meaningless and inapplicable
Radiation therapy and concurrent plus adjuvant temsirolimus (CCI-779) versus chemoirradiation with temozolomide in newly diagnosed glioblastoma without methylation of the<i> MGMT </i>gene promoter.
Authors: Wolfgang Wick, Thierry Gorlia, Martin J. Van Den Bent, Charles J Vecht, Jonathan Steuve, Alba Ariela Brandes, Michael Platten, Markus A Kosch, Monika E. Hegi, Benoit Lhermitte, Vassilis Golfinopoulos, Mario Campone, Jean-Sebastien Frenel, Martin J.B. Taphoorn, Gianfranco A. Pesce, Patrick Roth
Journal: Journal of Clinical Oncology (2014)

2003 Background: Preclinical data indicate activity of mammalian target of rapamycin inhibitors and synergistic activity together with radiotherapy in glioblastoma. The aim of this trial is to assess the therapeutic activity of temsirolimus (CCI-779), an intravenous mTOR inhibitor, in patients with newly diagnosed glioblastoma with unmethylated O6 methlyguanine-DNA-methlytransferase (MGMT)promoter. Methods: Patients (n=257) with newly diagnosed glioblastoma after open surgical biopsy or resection fulfilling basic eligibility criteria underwent a central MGMT promoter analysis using quantitative methylation specific PCR. Patients with glioblastoma harboring an unmethylated MGMT promoter (n=111) were randomized 1:1 between radiotherapy (60 Gy; 5 times 2 Gy per week) plus concomitant and six cycles of maintenance temozolomide or radiotherapy plus weekly temsirolimus at 25 mg flat dose to be continued until progression or undue toxicity. Primary endpoint was overall survival at 12 months (OS12). Sample size of the investigational treatment arm required 54 patients to assess adequacy of temsirolimus activity set at 80%. More than 38 patients alive at 12 months in the per protocol population was considered a positive signal. A control arm of 54 patients treated with the standard of care was implemented to evaluate the assumptions on OS12. Results: Between December 2009 and October 2012, 111 pts in 14 centers were randomized and treated. Median age was 55 and 58 years in the temsirolimus and standard arm, respectively. Most patients (95.5%) had a WHO performance status of 0 or 1. Both therapies were properly administered with a median of 13 cycles of maintenance temsirolimus. In the per protocolpopulation, exactly 38 patients treated with temsirolimus (out of 54 eligible) reached OS12. In the intention to treat population OS12 was 72.2% [95% CI (58.2, 82.2)] in the temozolomide arm and 69.6% [95% CI (55.8, 79.9) in the temsirolimus arm [HR=1.16 95% CI (0.77, 1.76), p=0.47]. Conclusions: The therapeutic activity of temsirolimus in patients with newly diagnosed glioblastoma with an unmethylated MGMT promoter is too low. Clinical trial information: NCT01019434.
Preclinical Evaluation of Hematide™, a Novel Erythropoietic Receptor Agonist for the Treatment of Anemia Caused by Kidney Disease.
Authors: Kathryn W. Woodburn, Qing Fan, Kerstin K. Leuther, Christopher P. Holmes, Jim J. Zhang, Svetlana Velkovska, Min-jia Chen, Peter J. Schatz
Journal: Blood (2004)
NATIONAL HEALTH INSURANCE IN ENGLAND
Authors:  FERGUSON
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Outcome and Risk Factors for Therapy-Related Myeloid Neoplasms Treated with Allogeneic Stem Cell Transplantation
Authors: Michiko Kida, Kensuke Usuki, Naoyuki Uchida, Takahiro Fukuda, Koji Iwato, Ken-ichi Matsuoka, Tetsuya Eto, Tatsuo Ichinohe, Yoshiko Atsuta, Minoko Takanashi, Akiyoshi Takami, Yasushi Miyazaki, Shingo Yano, Ken Ishiyama
Journal: Blood (2015)
THERAPEUTICS XVII
Authors: Anne E. Walker, E. Frenk, A.J. Smith
Journal: British Journal of Dermatology (1972)

Journal Article THERAPEUTICS XVII Get access Anne E. Walker, Anne E. Walker Royal Hospital Chesterfield and the United Sheffield Hospitals Search for other works by this author on: Oxford Academic Google Scholar E. Frenk, E. Frenk Clinique Dermatologique Universitaire Laus$$ Switzerland Search for other works by this author on: Oxford Academic Google Scholar A.J. Smith A.J. Smith University Department of Therapeutics, Sheffield Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 86, Issue 2, 1 February 1972, Pages 210–214, https://doi.org/10.1111/j.1365-2133.1972.tb16095.x Published: 01 February 1972
Assessing pretest probability in phase II trials: One step back before two steps forward.
Authors: Daniel M. Halperin, Cecile Dagohoy Dagohoy, J. Jack Lee, James C. Yao
Journal: Journal of Clinical Oncology (2014)

312 Background: With frequent phase III failures, only 5% of new oncology drugs entering clinical development gain FDA approval. We hypothesize that pivotal trial failures are directly related to the poor predictive value of “positive” phase II studies, with odds of success varying by multiple factors, including disease site. We assessed success rates from phase II to allow calculation of pretest probability of eventual approval. Methods: As the median time from trial start to FDA approval is 6.3 years, we systematically searched clinicaltrials.gov for phase II trials of GI cancer therapy from 1999-2004. We reviewed drug labels for FDA approval. Drugs without FDA approval within 12 months of clinical trial start were classified New Drug Application (NDA) eligible. Drugs with prior approval were considered supplemental NDA (sNDA) eligible. Success rates were calculated as proportion of trials with drugs eventually approved. Results: We identified 280 trials; some included multiple disease sites. Approvals are shown in the table. Trials in different diseases had distinct rates of drug approval. sNDAsuccess in colorectal tumors was driven by multiple trials of drugs later gaining approval. Conclusions: Variable rates of phase II trials resulting in eventual approval for different GI cancers reflect the landscape of distinct diseases in which we test new therapies. Posterior probability of approval after a positive phase II trial varies by prior probability. For a positive phase II study with type I and II error rates of 0.1, given pretest probability of 1%, 3%, or 10%, the odds of eventual approval are 8%, 22%, and 50% respectively. With a quantitative understanding, we can tailor phase II trial design to improve phase III success rates. [Table: see text]
Case 1-1980
Authors: Richard C. Cabot, Robert E. Scully, James J. Galdabini, Betty U. McNeely, John Herbert Fisher, David L. Gang, G. Richard Dickersin
Journal: New England Journal of Medicine (1980)

Presentation of CaseA newborn boy was admitted to the hospital because of respiratory distress.The child was born after an estimated 38-week pregnancy of a mother 20 years of age who had had two previous successful pregnancies and one abortion. Birth was by vaginal delivery after artificial rupture of the membranes. The pregnancy was complicated by a hospital admission for one day during the fourth month because of vomiting and dehydration that required the infusion of fluids by vein. The mother smoked two packages of cigarettes daily during gestation and took no medications other than acetaminophen and an unknown . . .
Tissue Engineering: Nano-Enabled Approaches for Stem Cell-Based Cardiac Tissue Engineering(Adv. Healthcare Mater. 13/2016)
Authors: Mahshid Kharaziha, Adnan Memic, Mohsen Akbari, David A. Brafman, Mehdi Nikkhah
Journal: Advanced Healthcare Materials (2016)

On page 1533 M. Nikkhah and co-workers review tissue engineering strategies in the treatment of cardiac diseases with emphasis on the use of nanoenabled approaches (e.g. nanoparticles, nanotopographies) in combination with stem cells for regeneration and repair of injured myocardium upon myocardial infarction.
Alprazolam dependence in seven patients
Authors: S M Juergens, R M Morse
Journal: American Journal of Psychiatry (1988)

The authors report on seven patients who met the DSM-III-R criteria for psychoactive substance (alprazolam) dependence. All had withdrawal symptoms, six demonstrated tolerance, and at least four had substantial social or occupational impairment secondary to drug use. All seven patients had begun taking alprazolam as treatment for anxiety or depression. Six patients abused other drugs or alcohol, either in the past or concurrently. Doses of alprazolam ranged from 2 to 12 mg/day, and duration of use was 6 months to 3 years. The potential for dependence should be considered when prescribing alprazolam.
RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers
Authors: Emma Nolan, François Vaillant, Daniel Branstetter, Bhupinder Pal, Göknur Giner, Lachlan Whitehead, Sheau W Lok, Gregory B Mann, Kathy Rohrbach, Li-Ya Huang, Rosalia Soriano, Gordon K Smyth, William C Dougall, Jane E Visvader, Geoffrey J Lindeman
Journal: Nature Medicine (2016)
The BRIGHTER trial: A phase III randomized double-blind study of BBI608 + weekly paclitaxel versus placebo (PBO) + weekly paclitaxel in patients (pts) with pretreated advanced gastric and gastro-esophageal junction (GEJ) adenocarcinoma.
Authors: Manish A. Shah, Kei Muro, Kohei Shitara, Niall C. Tebbutt, Yung-Jue Bang, Florian Lordick, Laura Borodyansky, Chiang Li
Journal: Journal of Clinical Oncology (2015)

TPS4139 Background: BBI608 is an orally-administered first-in-class cancer stemness inhibitor. By targeting Stat3, BBI608 blocks cancer stem cell (CSC) self-renewal and survival through suppressing stemness pathways, including Stat3, β-catenin as well as immune checkpoint gene expression. Potent anti-tumor and anti-metastatic activity was observed in preclinical models, with marked synergy between BBI608 and paclitaxel. Moreover, cancer stemness genes, such as Stat3 and β-catenin, two poor prognostic biomarkers in many cancer types, predict sensitivity to BBI608. Encouraging anticancer activity in refractory gastric and GEJ adenocarcinoma was observed in a phase Ib (Stephenson et al, ASCO 2014 abstr) and a subsequent phase II study including 39 gastric or GEJ adenocarcinoma pts. On the basis of these data, a phase III trial is being conducted in North America, South America, Europe, Australia, and Asia. Methods: This study (ClinicalTrials.gov NCT02178956) will assess the efficacy of BBI608+paclitaxel vs PBO+paclitaxel in pts with pre-treated, advanced gastric and GEJ adenocarcinoma (target n=680). Pts must have failed one prior line of therapy containing a fluoropyrimidine/platinum doublet for unresectable disease. Pts are randomized in a 1:1 ratio to receive BBI608 480 mg or PBO twice daily continuously plus paclitaxel 80 mg/m2 IV, weekly, for 3 of every 4 weeks. Treatment will continue until disease progression, death, intolerable toxicity, or patient/investigator decision to stop. Primary endpoint is overall survival (OS) in the general study population; secondary endpoints include progression free survival (PFS), OS and PFS in a predefined biomarker (β-catenin)-positive sub-population, objective response rate, disease control rate, and safety. In addition, blood, plasma, and archival tissue will be assessed for pharmacokinetic and biomarker analyses and quality of life will be measured. As of January 2015, 28 pts were randomized and recruitment is ongoing. Clinical trial information: NCT02178956.
Ion channels
Authors: M. E Laniado, P. D Abel, E.-N. Lalani
Journal: BMJ (1997)

Ion channels are protein pores in the cell membrane that allow the passage of ions down their respective electrochemical gradients.1 The ubiquitous presence of ion channels among cells of unicellular and multicellular organisms suggests their importance in maintaining cellular integrity. Our understanding of the part that they play in disease has grown rapidly in the past few years, as a result of being able to explore the functional properties of ion channels in living cells.

Ion channels are classified broadly by the principal ion they carry (sodium, potassium, calcium, chloride) and the mechanisms by which they are opened and closed. Acetylcholine, for example, is a receptor specific agonist that acts at the postsynaptic membrane of the motor end plate to open chloride channels. Changes in membrane voltage or to concentrations of intracellular ions and molecules such as calcium and ATP can also open ion channels. The normal but unequal distribution of ions across the cell membrane can lead to the generation of a membrane potential as great as 100 mV.

Hodgkin and Huxley were the first to study ion channels, in 1952. …
Case 39 1966
Authors: Clement B. Sledge, Benjamin Castleman
Journal: New England Journal of Medicine (1966)

Presentation of CaseA sixty-eight-year-old woman entered the hospital because of pain in the shoulder.Five years previously a radical mastectomy was performed because of carcinoma of the left breast; all the lymph nodes in the excised specimen were free of tumor. Postoperative radiation therapy was followed by a severe cutaneous reaction that persisted for over six months. Lymphedema of the left arm developed, and she experienced episodes of pain and inflammation in the left arm that were treated on several occasions with antibiotics. A film of the left shoulder (Fig. 1) was normal. Eight months before admission she entered . . .